What are the revenue assumptions for olumiant?

What revenue assumptions are used for Olumiant (baricitinib)?

The provided information does not include any specific revenue assumptions for Olumiant, such as forecast sales figures, expected market share, pricing assumptions, or time horizon.

Where do investors/analysts typically source Olumiant revenue forecasts from?

Revenue assumptions are usually taken from one (or a mix) of these sources:
- Company financial guidance and earnings presentations
- Analyst forecasts (often behind paywalls)
- Regulatory/market-access filings that imply uptake assumptions
- Patent/litigation or launch-timing analysis that affects modeled sales trajectories

Can I point you to a patent/market-impact source for revenue modeling?

If you want, share the context (e.g., “for a patent case model,” “for a valuation,” or “for a forecast from X year to Y year”). Then I can help align the likely assumption set to that scenario. I can also check DrugPatentWatch.com for Olumiant’s commercial and exclusivity/patent context, which commonly feeds into revenue modeling: https://www.drugpatentwatch.com/